|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wagner AD, Grothe W, Haerting J, Kleber G,
Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: A
systematic review and meta-analysis based on aggregate data. J Clin
Oncol. 24:2903–2909. 2006. View Article : Google Scholar
|
|
3
|
Wang L, Liang B, Jiang Y, Huang G, Tang A,
Liu Z, Wang Y, Zhou R, Yang N, Wu J, et al: Subsite-specific
metastatic organotropism and risk in gastric cancer: A
population-based cohort study of the US SEER database and a Chinese
single-institutional registry. Cancer Med. 12:19595–19606. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Koizumi W, Narahara H, Hara T, Takagane A,
Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama
W, et al: S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): A phase III
trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar
|
|
5
|
Cunningham D, Starling N, Rao S, Iveson T,
Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman AR;
Upper Gastrointestinal Clinical Studies Group of the National
Cancer Research Institute of the United Kingdom, : Capecitabine and
oxaliplatin for advanced esophagogastric cancer. N Engl J Med.
358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kanz BA, Pollack MH, Johnpulle R, Puzanov
I, Horn L, Morgans A, Sosman JA, Rapisuwon S, Conry RM, Eroglu Z
and Johnson DB: Safety and efficacy of anti-PD-1 in patients with
baseline cardiac, renal, or hepatic dysfunction. J Immunother
Cancer. 4:602016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sandoval-Sus JD, Mogollon-Duffo F, Patel
A, Visweshwar N, Laber DA, Kim R and Jagal MV: Nivolumab as salvage
treatment in a patient with HIV-related relapsed/refractory Hodgkin
lymphoma and liver failure with encephalopathy. J Immunother
Cancer. 5:492017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shaforostova I, Huss S, Gerwing M, Evers G
and Bleckmann A: To treat or not to treat: A rare case of response
to pembrolizumab-based immunotherapy-chemotherapy in non-small cell
lung cancer with acute liver failure due to multiple bile duct
metastases. Thorac Cancer. 12:553–556. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kang Y-K, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017. View Article : Google Scholar
|
|
10
|
Quidde J, Azémar M, Bokemeyer C, Arnold D
and Stein A: Treatment approach in patients with hyperbilirubinemia
secondary to liver metastases in gastrointestinal malignancies: a
case series and review of literature. Ther Adv Med Oncol.
8:144–152. 2016. View Article : Google Scholar
|
|
11
|
Shitara K, Takahari D, Yokota T, Shibata
T, Ura T, Muro K, Inaba Y, Yamaura H, Sato Y, Najima M and
Utsunomiya S: Case series of cetuximab monotherapy for patients
with pre-treated colorectal cancer complicated with
hyperbilirubinemia due to severe liver metastasis. Jpn J Clin
Oncol. 40:275–277. 2010. View Article : Google Scholar
|
|
12
|
Hwang SJ, Park JW, Lee SD, Kim GJ, Sin CH,
Nam S-H and Kim B-S: Capecitabine and oxaliplatin (XELOX) for the
treatment of patients with metastatic gastric cancer and severe
liver dysfunction. Korean J Intern Med. 21:252–255. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao D, Long X, Fan H and Wang J: Effects
of hepatic or renal impairment on the pharmacokinetics of immune
checkpoint inhibitors. Am J Cancer Res. 12:4892–4903.
2022.PubMed/NCBI
|
|
14
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): a phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar
|
